Approvals/TGA/BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in pre-filled syringe

Approved

STANDARD

BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in pre-filled syringe

Approval Id: d2f677fea8ba59a1
Product Name: BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in pre-filled syringe
Artg Id: 313681
Artg Name: BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in pre-filled syringe
Sponsor: Novartis Pharmaceuticals Australia Pty Ltd
Company Detail Path: /organization/novartis-pharmaceuticals-australia-pty-ltd
Artg Date: 2020-01-16
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/c6b630585415ea0c7c071a41ed5a1aae.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/3d979f1621ac96e1327b2387969928db.pdf

Approved

Agency

TGA

Country

🇦🇺

Approval Date

Dec 9, 2025

Approval ID

d2f677fea8ba59a1

Type

Standard